The competition between 5 companies over their generic versions of Pfizer’s breast cancer treatment ‘Ibrance (palbociclib)’ is heating up. Kwang Dong Pharmacuetical, Shinpoong Pharm, Daewoong Pharmaceutical, and Boryung Pharmaceutical each challenged Pfizer to overcome the crystalline form patent and formulation patent of Ibrance.

In terms of acquiring first generic exclusivity, Kwang Dong Pharmacuetical has been leading the race. It is the only company that completed the bioequivalence test for its generic and received marketing authorization.

According to industry sources on the 18th, Shinpoong Pharm recently filed a trial to confirm the passive scope of rights of Ibrance’s formula